This is an important evidence of how the PDL-1/PD-1 suppressive pathway is also relevant in the GBM tumor microenvironment; the fact that different trials involving anti-PD-1/PDL-1 drugs have failed should thus be imputed to additional mechanisms involved in effector T-cell impairment. Here, CD274 is linked to neoplasm.